| International Bioimmune Systems' products for treatment and detection of cancer provide a portfolio of tools for cancer management. Its therapeutic human/mouse antibody has been licensed to a pharmaceutical partner for treatment of colon cancer and is being scaled up for FDA clinical trials in advanced cancer patients. A physician's office diagnostic kit, in contrast to costly procedures such as colonoscopy, is being develped with collaborators at the Mayo Clinic for early detection of colon cancer. The Company is also producing an imaging reagent, to replace or enhance CAT scan procedures for the localization of metastases. Similar products for lung cancer as well as other tumors are being developed. |
| In the past, the Company purified several immunogenic tumor associated antigens which were shown to be capable of stimulating an anticancer immune response, benefiting patients enrolled in clinical studies by markedly increasing their chances for survival. The Company subsequently developed a panel of proprietary and unique monoclonal antibodies of exceptional specificity which form the basis of its core technology. |
| The principals Myron Arlen, MD, President; Jon Gershoni, PhD, CEO and Director of Product Development; and Andrew Lin, Esq, CFO provide the Company with expertise and experience in practical aspects of cancer medicine, molecular biology, marketing, business and effective management. |
Panelists:
 |
Lawrence J. Blumberg, M.D., Vice President, Alliance Capital Management Corporation |
|
Aby Buchbinder, M.D., Medical Oncologist, North Shore University Hospital |
|
Edward Chait, Ph.D., Senior Vice President, Business Development, Intergen Company |
|
Joann Conklin, President, The JENC Group Philip N. Sussman, Vice President Corporate Development, Cadus Pharmaceutical Corporation |
|
| DATE: |
Wednesday evening, October 21, 1998 |
| PLACE: |
Chase Manhattan Bank, 270 Park Ave. (47th St.), NYC. 11th Floor |
|
|